Articles tagged with Target Proteins
A new genomics study has helped guide the development of vaccines against Shigella, a leading cause of severe diarrhoea in children. The research revealed the extent of genomic diversity among Shigella species, highlighting challenges to current vaccine approaches.
Researchers identified water molecules' impact on protein dynamics and drug target residence time, suggesting that a long target residence time can be important for drug efficacy. This understanding enables more rational drug design in the early stages of drug discovery projects.
A team of Weill Cornell Medicine investigators created a comprehensive atlas, called Tau interactome, that maps all the Tau protein's interactions with other proteins in human neurons. They found that mutations diminish Tau-mitochondrial protein interaction may hamper energy production and lead to cognitive decline.
Researchers identified a mechanism by which two antiviral genes, SAMD9 and SAMD9L, promote childhood cancer when mutated. The study found that this protein region performs the toxic function through binding to nucleic acids.
Researchers successfully engineered mesenchymal stromal cells to carry and deliver therapeutics specifically to targeted tissues, offering a precise and reliable approach for treating diseases. This novel cargo-carrier, dubbed 'Cargocytes,' retains most of its cellular functionality while greatly enhancing therapeutic capacity.
Scientists at WEHI have produced the first molecular images of RNF216, an enzyme controlling protein signalling in human cells. The discovery sheds light on its role in a rare group of hereditary neurodegenerative diseases, including Gordon-Holmes Syndrome.
Researchers at Waseda University discovered a new protein isoform called Senp5S, which helps regulate Drp1 and mitochondrial dynamics during brain development. The study suggests a novel and vital role for post-translational SUMOylation in neuronal differentiation.
An AI-driven solution identifies sites on RNA and DNA molecules where interaction with potential drug candidates can occur. This allows pharmaceutical companies to discover new medications in a more focused and efficient manner.
Researchers at WVU are studying the Musashi proteins to understand their role in retinal degeneration and develop a universal therapy. By investigating protein translation and gene suppression, they hope to identify potential pathways to boost protein production and slow vision loss.
Researchers identified antibodies targeting conserved sites on the spike protein, showing promise against future variants. Antibodies from vaccinated individuals retained some activity, while those with prior infection had reduced effectiveness.
Researchers identify a previously overlooked site on the HA protein, known as the 'anchor epitope', which can neutralize a wide range of influenza strains. This discovery has significant implications for the development of universal influenza vaccines and antibody therapies.
Scientists have discovered recently evolved regions in the 'dark genome' that code for proteins associated with schizophrenia and bipolar disorder. These protein biomarkers could help distinguish between the two conditions and identify patients at risk of psychosis or suicide.
Researchers at UCLA have identified rare T cells capable of targeting a protein found in SARS-CoV-2 and other coronaviruses. By adding a fragment of this protein to vaccines, they hope to create a longer-lasting immune response and increase protection against new variants. This breakthrough could lead to more effective COVID-19 vaccines.
A case study published in Nature Medicine reports a patient experiencing progressive neurological features resembling Parkinson's disease after CAR-T cell therapy, suggesting potential neurotoxicity. The study highlights the importance of monitoring for neurotoxicity in patients receiving BCMA-targeted CAR-T therapies.
Researchers at the University of Bath have optimised a peptide that prevents alpha-synuclein misfolding, a key feature of Parkinson's disease. The new molecule, 4654W(N6A), has shown significant promise in lab experiments and could lead to the development of a disease-modifying treatment.
Chemists at UNIGE have developed a new method to rapidly generate millions of molecule combinations using DNA-pairing processes, finding the best match for target proteins within two weeks. This technique uses evolutionary forces to amplify the best combinations and generates diversity.
A research team developed an AI framework that analyzes protein interactions to predict effective and low-toxicity cancer drug combinations. The framework, GraphSynergy, outperforms conventional models in identifying synergistic combinations.
Researchers at Vanderbilt University have identified a new target for rapid antidepressant drugs using ketamine's role in synaptic effects. This breakthrough could lead to new treatments for approximately half of patients whose current antidepressants are ineffective, significantly reducing the risk of suicide.
Researchers have discovered a new target for COVID-19 vaccines that could complement existing vaccines by inducing an immune response against 'replication proteins', essential for the viral cycle. The approach may lead to the creation of a pan-coronaviruses vaccine protecting against SARS-CoV-2 and other coronaviruses.
New study suggests inhibiting Shp2 in tumor cells may boost tumor growth and survival, complicating its use as a potential cancer therapy for HCC.
A USF Health study reveals that fibrinogen can directly interact with neurons, leading to inflammation and neurodegeneration in Alzheimer's disease and traumatic brain injury. The researchers found that blocking the binding of fibrinogen to its receptors may alleviate short-term memory problems associated with these diseases.
Scientists from Japan discover IL-36Ra plays a pivotal role in wound healing, and Cl-amidine normalizes exacerbated I/R injury. The study's findings suggest IL-36Ra as a potential therapeutic target for cutaneous I/R injuries.
Researchers at Children's Hospital of Philadelphia have developed a novel therapy that targets proteins essential for tumor growth and survival. Using a multi-omics approach, they identified peptides unique to neuroblastoma tumors, which are then targeted by peptide-centric chimeric antigen receptors (PC-CARs).
A team of experts from Tel Aviv University has identified 5 coronavirus proteins responsible for damaging blood vessels. The researchers hope that the identification will lead to the development of targeted drugs that reduce vascular damage in COVID-19 patients.
Itepekimab, a novel monoclonal antibody, has been found to be safe and effective in treating moderate-to-severe asthma. In a phase 2 trial, it significantly improved lung function and reduced asthma control events compared to placebo.
Researchers identified two nanobodies that specifically target and stabilize the tetrameric form of SARS-CoV-2 non-structural protein Nsp9, potentially repressing viral replication. These findings suggest a new antiviral strategy for diagnosis and treatment against COVID-19.
Researchers developed a novel sensor that can detect SARS-CoV-2 proteins without antibodies, giving results within minutes. The technology enables rapid diagnostics for Covid-19 and future pandemics, reducing economic loss.
Researchers developed a new protein treatment that prevents glaucoma from forming in mice and reduces pressure in the eyes. The study provides new targets for therapies and aims to develop an injectable treatment for patients.
University of Illinois Chicago researchers discovered a function of mammalian target of rapamycin complex 2 in an antiviral defense mechanism, limiting HSV-1 virus infection through rapid activation of antiviral immunity. The protein complex protects the host by preventing encephalitis and possible death due to HSV-1 infection.
Researchers identified a pattern that links the accumulation of amyloid beta (Aβ) proteins with a reduction of serotonin, which may help predict who will develop late-life depression. The study found that individuals expressing this pattern had more severe depressive symptoms.
Researchers have discovered a new drug target for myelodysplastic syndrome (MDS) and other hematologic malignancies, which are sensitive to MEK inhibitors. The study found that mutations affecting RNA splicing alter cells to develop MDS and solid tumors, providing a potential new approach to treating this rare blood cancer.
Researchers found that asymptomatic patients may not produce significant IgG antibodies, but rather a different kind of antibody count that can indicate disease severity. The study suggests using the ratio of these two counts as a marker to determine if a person has had COVID-19.
Researchers found a correlation between high levels of Gas6 and zika-induced neurological complications. Gas6 helps the virus invade human cells, facilitating viral replication and aggravating infection. The discovery paves the way for future research on developing drugs to combat the virus.
Scientists have discovered the working mechanism of an important class of drug target receptor proteins, shedding light on their role in the body's immune response. The study highlights a novel approach to targeting these receptors and blocking excessive cytokine release, which could lead to new treatments for COVID-19.
Researchers at Uppsala University have designed new antibodies that bind to both large and small aggregates of the amyloid-beta protein, potentially providing a more effective treatment for Alzheimer's disease. The new antibody format is stronger in binding to clumps and can also target smaller aggregates.
A study analyzed genetic material from 86 discordant couples infected by SARS-CoV-2 and found associations between certain genetic variants and efficient activation of natural killer cells. These cells play a crucial role in the innate immune response, destroying infected cells to prevent disease development.
New targeted therapies are being developed to target genetic alterations in cancer cells, such as the ARID1A mutation found in 10-50% of solid tumours. Early clinical trials suggest that these agents may be effective in treating multiple cancers, including breast, ovarian, and gastric cancer.
A global collaboration has identified three groups of antibodies resistant to mutations in the SARS-CoV-2 Spike protein, which could target vulnerable sites on the protein. The study provides a framework for selecting durable antibody cocktails for COVID-19 treatment and will guide the development of more effective antibody therapies.
A study published in Nature Communications reveals the mechanisms of SARS-CoV-2 proteolysis and identifies key cellular substrates with therapeutic potential. The research provides a powerful resource for developing targeted strategies to inhibit the virus, which has caused over 227 million infections and 4.6 million deaths worldwide.
Researchers at Johns Hopkins Medicine have identified promising new targets for pancreatic cancer treatment and early detection, including glycosylated proteins that could be captured in the blood for diagnosis. The study also suggests new ways to improve immune response to these tumors.
Researchers designed novel molecules that bound tightly to SARS-CoV-2's molecular scissors, inhibiting the virus's replication. The breakthrough could lead to new treatments for COVID-19.
Researchers developed a treatment using cowpea mosaic virus nanoparticles that target lung tumors, slowing tumor growth and preventing cancer spread. The treatment showed efficacy against aggressive cancer cell lines and may offer protection to patients at high risk of metastatic disease.
Researchers at University of Illinois Chicago found a potential direct connection between neurodegenerative diseases, such as Alzheimer's disease, amyotrophic lateral sclerosis (ALS), glaucoma, and herpesvirus. The study suggests OPTN protein restricts HSV-1 virus spread in cells.
Researchers at UNSW Sydney have found the specific protein responsible for keeping cells attached to collagen, a key finding for cancer research. The discovery could lead to new directions for cancer treatment by targeting the protein tropomyosin, which is involved in forming the anchor's chain.
Researchers found that viral fossils in Australian marsupials are used to make non-coding RNAs that protect against outside infection. The study suggests that these viral fossils may be helping to immunize animals, potentially providing a mechanism similar to vaccination.
Scientists at CIBFar have discovered the molecular mechanism of SARS-CoV-2's main protease, which enables the virus to replicate in host cells. The study provides valuable insights into the process and has immediate applications for developing antiviral drugs.
Researchers at McGill University identified proteins that drive cancer stem cells in brain tumours. Targeting the protein galectin1 may provide a more effective treatment for glioblastoma when combined with radiation therapy. The study found significant improvement in tumour response to radiation therapy, resulting in expanded lifespan.
A CRISPR screening tool identified ZMYND8, an epigenetic regulatory protein, as a potential new therapeutic target for acute myeloid leukemia. Inhibiting ZMYND8 has been shown to leave cancer cells with smaller tumors and better survival in mouse models.
Researchers have determined the structure of human leukotriene B4 receptor 1 (hBLT1), a protein involved in inflammation and disease. The analysis reveals how the receptor recognizes its binding partners and interacts with them, opening up avenues for designing better drugs.
Researchers at UB aim to reduce unwanted toxicity in cancer treatments by combining antibody-drug conjugates with payload-binding selectivity enhancers. The five-year study may lead to safer and more effective treatments for 1.8 million US cancer patients.
Researchers have discovered that toxic animals produce 'toxin sponges' to mop up deadly toxins and prevent them from binding to vital proteins. This alternative autoresistance strategy may offer a general means of toxin protection, including the development of antidotes against various toxic agents.
Researchers have developed a neural network model called BiteNetPp to detect protein-peptide binding sites, enabling the design of peptide-based drugs. The model consistently outperforms existing methods and can analyze a single protein structure in under a second, making it suitable for large-scale studies.
A comprehensive molecular map of lung squamous cell carcinoma has identified potential new drug targets, including the gene NSD3, and highlighted immune regulation pathways that could help cancer evade immunotherapies. The study's findings have also revealed metabolic dysregulation and crosstalk between different cellular processes.
Researchers have identified a promising therapeutic target, METTL1, to treat aggressive cancers by inhibiting an RNA-modifying protein. The study found that targeting METTL1 effectively destroys cancer cells in laboratory models and mice while leaving healthy cells unharmed.
Researchers at the University of Oregon used CRISPR-Cas9 gene editing to target a specific mutation causing Fuchs' corneal dystrophy, preserving endothelial cell density and function. The study lays the groundwork for future research on using this technique to treat genetic disorders in post-mitotic cells.
Researchers at ETH Zurich used AI to identify target molecules of natural substances, paving the way for a new class of pharmaceutical agents. The algorithm successfully predicted human receptors and enzymes that interact with natural compounds, leading to the discovery of simpler, cheaper alternatives.
A team of researchers from Tokyo University of Agriculture and Technology has developed a new approach to identifying and tagging specific proteins. They used multivalent gold nanoparticles as a scaffold to attach carbohydrate ligands and electrophiles, which allowed them to highly efficiently and selectively label carbohydrate-binding...
Scientists developed a CRISPR-Cas9-based tool that induces long-term gene silencing by epigenetic editing, offering potential treatment options for cancer and genetic ailments. The innovative dCas9-KAL construct achieves stable repression of target genes.
A new way to target the RAS protein, responsible for 20-30% of all known cancers, has been found by a team from the University of Leeds. This breakthrough could lead to greater treatments for more patients, paving the way for hundreds of other disease targets.
A new study reveals 200 previously approved drugs that could be repurposed to treat COVID-19, with 40 already undergoing clinical trials. The research identified key proteins targeted by these drugs and found potential antiviral compounds, including proguanil and sulfasalazine.